TY - JOUR
T1 - Small dense low-density lipoprotein cholesterol and the risk of coronary heart disease in a japanese community
AU - Higashioka, Mayu
AU - Sakata, Satoko
AU - Honda, Takanori
AU - Hata, Jun
AU - Yoshida, Daigo
AU - Hirakawa, Yoichiro
AU - Shibata, Mao
AU - Goto, Kenichi
AU - Kitazono, Takanari
AU - Osawa, Haruhiko
AU - Ninomiya, Toshiharu
N1 - Funding Information:
Toshiharu Ninomiya received research funding from DENKA SEIKEN Co., Ltd. The other authors declare that they have no conflicts of interest.
Funding Information:
We would like to gratefully and sincerely thank Professor Yoshinao Oda, Professor Toru Iwaki, and their colleagues at the Department of Anatomic Pathology and Department of Neuropathology, Graduate School of Medical Sciences, Kyushu University, who provided expertise and insight into the autopsy findings that greatly assisted our research. The statistical analyses were carried out using the computer resources offered under the category of General Projects by the Research Institute for Information Technology, Kyushu University. This study was supported in part by Grants-inAid for Scientific Research (A) (JP16H02692) and (B) (JP16H05850, JP17H04126, and JP18H02737) and (C) (JP17K09114, JP17K09113, JP17K01853, JP18K07565, JP18K09412, and JP19K07890) and (Early-Career Scientists) (JP18K17925, and JP18K17382) from the Ministry of Education, Culture, Sports, Science and Technology of Japan; by Health and Labour Sciences Research Grants of the Ministry of Health, Labour and Welfare of Japan (H29-Junkankitou-Ippan-003, and H30-Shokuhin-[Sitei]-005); and by the Japan Agency for Medical Research and Development (JP19dk0207025, JP19ek0210082, JP19ek0210083, JP19km0405202, JP19ek0210080, JP19fk0108075). In addition, this study was sponsored by DENKA SEIKEN Co., Ltd. (Tokyo, Japan). The sponsor of the study had no role in the study design, conduct of the study, data collection, data interpretation or preparation of the report.
Publisher Copyright:
© 2020 Japan Atherosclerosis Society.
PY - 2020
Y1 - 2020
N2 - Aims: This study aims to investigate the association between serum small dense low-density lipoprotein (sdLDL) cholesterol level and the development of coronary heart disease (CHD) in a Japanese community. Methods: A total of 3,080 participants without prior cardiovascular disease, aged 40 years or older, were followed up for 8 years. The participants were divided into the quartiles of serum sdLDL cholesterol levels. The risk estimates were computed using a Cox proportional hazards model. Results: During the follow-up period, 79 subjects developed CHD. Subjects in the highest quartile had a 5.41-fold (95% confidence interval, 2.12–13.82) higher risk of CHD than those in the lowest quartile after controlling for confounders. In the analysis classifying the participants into four groups according to the levels of serum sdLDL cholesterol and serum low-density lipoprotein (LDL) cholesterol levels, the risk of CHD almost doubled in subjects with sdLDL cholesterol of ≥ 32.9 mg/dL (median), regardless of serum LDL cholesterol levels, as compared with subjects with serum sdLDL cholesterol of ＜32.9 mg/dL and serum LDL cholesterol of ＜120.1 mg/dL (median). When serum sdLDL cholesterol levels were incorporated into a model with known cardiovascular risk factors, c-statistics was significantly increased (from 0.77 to 0.79; p =0.02), and the net reclassification improvement was also significant (0.40; p＜0.001). Conclusions: The present findings suggest that the serum sdLDL cholesterol level is a relevant biomarker for the future development of CHD that offers benefit beyond the serum LDL cholesterol level and a possible therapeutic target to reduce the burden of CHD in a Japanese community.
AB - Aims: This study aims to investigate the association between serum small dense low-density lipoprotein (sdLDL) cholesterol level and the development of coronary heart disease (CHD) in a Japanese community. Methods: A total of 3,080 participants without prior cardiovascular disease, aged 40 years or older, were followed up for 8 years. The participants were divided into the quartiles of serum sdLDL cholesterol levels. The risk estimates were computed using a Cox proportional hazards model. Results: During the follow-up period, 79 subjects developed CHD. Subjects in the highest quartile had a 5.41-fold (95% confidence interval, 2.12–13.82) higher risk of CHD than those in the lowest quartile after controlling for confounders. In the analysis classifying the participants into four groups according to the levels of serum sdLDL cholesterol and serum low-density lipoprotein (LDL) cholesterol levels, the risk of CHD almost doubled in subjects with sdLDL cholesterol of ≥ 32.9 mg/dL (median), regardless of serum LDL cholesterol levels, as compared with subjects with serum sdLDL cholesterol of ＜32.9 mg/dL and serum LDL cholesterol of ＜120.1 mg/dL (median). When serum sdLDL cholesterol levels were incorporated into a model with known cardiovascular risk factors, c-statistics was significantly increased (from 0.77 to 0.79; p =0.02), and the net reclassification improvement was also significant (0.40; p＜0.001). Conclusions: The present findings suggest that the serum sdLDL cholesterol level is a relevant biomarker for the future development of CHD that offers benefit beyond the serum LDL cholesterol level and a possible therapeutic target to reduce the burden of CHD in a Japanese community.
UR - http://www.scopus.com/inward/record.url?scp=85087426170&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087426170&partnerID=8YFLogxK
U2 - 10.5551/jat.51961
DO - 10.5551/jat.51961
M3 - Article
C2 - 31708527
AN - SCOPUS:85087426170
SN - 1340-3478
VL - 27
SP - 669
EP - 682
JO - Journal of atherosclerosis and thrombosis
JF - Journal of atherosclerosis and thrombosis
IS - 7
ER -
